Combined alkylation and histone deacetylase inhibition with EDO-S101 has significant therapeutic activity against brain tumors in preclinical models

Yushi Qiu; Zhimin Li; John A. Copland; Thomas Mehrling; Han W. Tun

doi:10.18632/oncotarget.25588

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Research Papers:

Combined alkylation and histone deacetylase inhibition with EDO-S101 has significant therapeutic activity against brain tumors in preclinical models

Yushi Qiu, Zhimin Li, John A. Copland, Thomas Mehrling and Han W. Tun _

PDF | HTML | How to cite

Oncotarget. 2018; 9:28155-28164. https://doi.org/10.18632/oncotarget.25588

Metrics: PDF 1235 views | HTML 1595 views | ?

Abstract

Yushi Qiu1, Zhimin Li1, John A. Copland1, Thomas Mehrling3 and Han W. Tun1,2

1Department of Cancer Biology, Mayo Clinic, Jacksonville, FL 32224, USA

2Division of Hematology and Medical Oncology, Mayo Clinic, Jacksonville, FL 32224, USA

3Mundipharma-EDO GmbH, 4052 Basel, Switzerland

Correspondence to:

Han W. Tun, email: [email protected]

Keywords: EDO-S101; brain tumors; CNS lymphoma; glioblastoma multiforme; metastatic breast cancer of the brain

Received: November 27, 2017 Accepted: May 24, 2018 Published: June 15, 2018

ABSTRACT

There is a clear unmet need for novel therapeutic agents for management of primary and secondary brain tumors. Novel therapeutic agents with excellent central nervous system (CNS) penetration and therapeutic activity are urgently needed. EDO-S101 is a novel alkylating and histone deacetylase inhibiting agent created by covalent fusion of bendamustine and vorinostat.

We used murine models to perform CNS pharmacokinetic analysis and preclinical therapeutic evaluation of EDO-S101 for CNS lymphoma, metastatic triple-negative breast cancer of the brain, and glioblastoma multiforme. EDO-S101 has excellent CNS penetration of 13.8% and 16.5% by intravenous infusion and bolus administration respectively. It shows promising therapeutic activity against CNS lymphoma, metastatic triple-negative breast cancer of the brain, and glioblastoma multiforme with significant prolongation of survival compared to no-treatment controls. Therapeutic activity was higher with IV infusion compared to IV bolus. It should be evaluated further for therapeutic use in brain tumors.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 25588

Publication Alerts

Research Papers:

Combined alkylation and histone deacetylase inhibition with EDO-S101 has significant therapeutic activity against brain tumors in preclinical models

Abstract